Verastem Inc
F:2VSA
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Verastem Inc
F:2VSA
|
US |
|
A
|
Aevis Victoria SA
SIX:AEVS
|
CH |
|
thyssenkrupp AG
MIL:1TKA
|
DE |
|
N
|
National Beverage Corp
F:20V
|
US |
|
M
|
Molson Coors Canada Inc
F:65K
|
CA |
|
M
|
Microtips Technology Inc
TPEX:3285
|
TW |
|
Inventec Corp
TWSE:2356
|
TW |
|
N
|
NetApp Inc
XMUN:NTA
|
US |
|
R
|
Ryder System Inc
SWB:RYD
|
US |
|
Neurones SA
F:NE9
|
FR |
Earnings Calls
Last Earnings Call
Revenue rebound: Verastem reported $25.1 million of net product revenue, and management said the AVMAPKI FAKZYNJA CO-PACK launch rebounded meaningfully versus the prior quarter.
Balance sheet boost: The company added $90 million of non-dilutive funding through a royalty deal with Oberland Capital and a Secura Bio milestone, bringing pro forma cash to $201.4 million.
Pipeline progress: Verastem said it completed target enrollment in the dose-expansion cohorts for VS-7375, started all three Phase II registration-directed studies, and expects an October data update.
Commercial momentum: Management said CO-PACK growth was driven by more new patient starts, more refills, broader physician adoption, and earlier-line use in both academic and community settings.
Outlook: The company reiterated that the LGSOC business should become self-sustaining by the end of 2026 and said cash plus future revenue should fund operations into the second half of 2027.
Partnership interest: Management said it continues to work on the Erasca partnership, remains interested in PRMT5, and has seen considerable inbound interest from strategics.